healthcare-thumbnail.png

Non-Small Cell Lung Cancer Market Research Report

Published: 2025 - January

Report Code: VMR-17623

Region: Global

Request Sample
Customization
Ask an Expert
Enquire Enquire Before Buying

Non-Small Cell Lung Cancer Market Analysis

The Non-Small Cell Lung Cancer (NSCLC) market represents a critical and rapidly evolving segment within oncology. NSCLC, accounting for the majority of lung cancer cases, encompasses adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, with significant advancements in targeted therapies and immuno-oncology reshaping treatment paradigms. Driven by the increasing adoption of biomarker-based treatments, precision medicine, and combination therapies, the NSCLC market is positioned for substantial growth and innovation.

Disruptive Impact and Opportunities:

Breakthrough targeted therapies such as datopotamab deruxtecan and KRAS inhibitors like JDQ443 and MRTX849 are redefining patient outcomes by addressing previously untargetable mutations. The development of oral administration options and patient-centric drug delivery mechanisms streamline treatments for improved compliance. Next-generation immunotherapies, including INBRX-106, are designed to minimize side effects while maximizing therapeutic efficacy. The market’s growing pipeline of drugs and expanded biomarker testing infrastructure cater to broader patient populations, driving significant scalability.

Non-Small Cell Lung Cancer Market Segmentation - Emerging Drugs

  • Datopotamab deruxtecan

  • JDQ443

  • MRTX849

  • INBRX-106

Non-Small Cell Lung Cancer Market Segmentation - Marketed Drugs

  • KEYTRUDA (pembrolizumab)

  • LIBTAYO (cemiplimab-rwlc)

Key Companies:

  • BridgeBio Pharma

  • Daiichi Sankyo

  • EMD Serono/Merck

  • AbbVie/Pfizer

  • Eli Lilly and Company

  • BioNTech SE

  • Shenzhen TargetRx

  • Taiho Pharmaceutical

  • Chong Kun Dang

  • Bristol Myers Squibb

Non-Small Cell Lung Cancer Market Segmentation - By Type

  • Adenocarcinoma

  • Squamous Cell Carcinoma

  • Large Cell Carcinoma

  • Other Histological Subtypes

Non-Small Cell Lung Cancer Market Segmentation -  By Administration Type

·  Oral

·  Injectable

  • Intravenous

  • Subcutaneous

What’s in It for You?

  • Identify emerging and marketed therapies shaping the competitive landscape.

  • Leverage actionable insights into biomarker-driven innovation.

  • Explore partnership opportunities with leading players.

  • Strategize market entry and expansion using detailed forecasts and trends.

Non-Small Cell Lung Cancer Market Analysis (Market Size & CAGR, Epidemiology, Marketed Therapies, Emerging Drugs, Clinical Trials, Key Approvals & Anticipated Loss of Exclusivity, Opportunities, Unmet Needs, Company Profiles)

1. Non-Small Cell Lung Cancer Market - Executive Summary                                        

               1.1. Introduction                             

               1.2. Objectives                 

               1.3. Key Findings                             

                              1.3.1. Market Size 2022 & 2032: By Key Country (10MM)

                              1.3.2. Global Market Size 2022 & 2032: By Key Segment  

                              1.3.3. Key Investments & Startup Analysis             

               1.4. Research Methodology                        

                                            

2. Understanding the Disease                                   

               2.1. Disease Overview                   

               2.2. Classification                            

               2.3. Signs and Symptoms                             

               2.4. Risk Factors              

               2.5. Causes                       

               2.6. Disease Biology & Digital Innovations                            

               2.7. Stages & Staging System                     

               2.8. Diagnostic Algorithm                            

               2.9. Current Treatment Practices & Algorithm                     

               2.10. Current Standard of Care and Treatment Gaps                        

               2.11. Patient Demographics and Treatment Pathways                     

                                            

3. Guidelines                                    

                                            

4. Unmet Needs                                            

                                            

5. Epidemiology and Patient Population                                

               5.1. Epidemiology Key Findings                  

               5.2. Assumptions and Rationale: 10MM                

               5.3. Epidemiology Scenario: 10MM                         

               5.4. U.S. Epidemiology Scenario                

               5.5. EU-5 Epidemiology                 

                              5.5.1. U.K. Epidemiology Scenario            

                              5.5.2. Germany Epidemiology Scenario   

                              5.5.3. France Epidemiology Scenario       

                              5.5.4. Italy Epidemiology Scenario            

                              5.5.5. Spain Epidemiology Scenario          

               5.6. Japan Epidemiology Scenario                            

               5.7. China Epidemiology Scenario                            

               5.8. Australia Epidemiology Scenario                      

               5.9. India Epidemiology Scenario                             

                                            

6. Real-world Data & Real-world Evidence                                           

                                            

7. Drug Development Landscape                                            

               7.1. Existing Key Drug Candidate Profiles/ Marketed Therapies                    

                              7.1.1. KEYTRUDA (pembrolizumab)           

                                             7.1.1.1. Product Description

                                             7.1.1.2. Regulatory Milestones

                                             7.1.1.3. Other Developmental Activities

                                             7.1.1.4. Pivotal Clinical Trials

                                             7.1.1.5. Ongoing Current Pipeline Activity

                              7.1.2. LIBTAYO (cemiplimab-rwlc)              

                                             7.1.2.1. Product Description

                                             7.1.2.2. Regulatory Milestones

                                             7.1.2.3. Other Developmental Activities

                                             7.1.2.4. Pivotal Clinical Trials

                                             7.1.2.5. Ongoing Current Pipeline Activity

               7.2. Competitive Analysis and Differentiation                      

               7.3. Overview of Similar/Competing Drugs in Clinical Trials                           

               7.4. Future Trends and Emerging Drugs                 

                              7.4.1. Datopotamab deruxtecan 

                                             7.4.1.1. Product Description

                                             7.4.1.2. Clinical Development

                                             7.4.1.3. Safety and Efficacy

                              7.4.2. JDQ443    

                                             7.4.2.1. Product Description

                                             7.4.2.2. Clinical Development

                                             7.4.2.3. Safety and Efficacy

                              7.4.3. MRTX849

                                             7.4.3.1. Product Description

                                             7.4.3.2. Clinical Development

                                             7.4.3.3. Safety and Efficacy

                              7.4.4. INBRX-106             

                                             7.4.4.1. Product Description

                                             7.4.4.2. Clinical Development

                                             7.4.4.3. Safety and Efficacy

                                            

8. Regulatory Strategy and Potential Challenges                                

               8.1. Regulatory Pathways in Key Markets                             

               8.2. Anticipated Regulatory Hurdles and Mitigation Strategies                     

               8.3. Case Studies in Oncology Drug Regulation                    

               8.4. Impact of Potential Changes to Regulatory Framework                          

                                            

9. Commercial Landscape                                          

               9.1. Market Size & Growth Rates                             

               9.2. Key Approvals & Anticipated Loss of Exclusivity                         

               9.3. PESTLE & Porter’s Five Forces Analysis                          

               9.4. Market Shares, Positioning/Ranking                

               9.5. Market Drivers                        

               9.6. Identification of Threats                      

               9.7. Digital Evolution in Commercialization                           

                                            

10. Market Segmentation                                           

               10.1. Market by Therapy Type                   

                              10.1.1. Chemotherapy   

                              10.1.2. Targeted Therapy             

                              10.1.3. Immunotherapy 

                              10.1.4. Other     

               10.2. Market by Type                    

                              10.2.1. Squamous Cell Carcinoma            

                              10.2.2. Large Cell Carcinoma       

                              10.2.3. Adenocarcinoma               

                              10.2.4. Others   

                                            

11. Pricing, Reimbursement, and Access                              

               11.1. Competitive Pricing Analysis                           

               11.2. Reimbursement Landscape and Challenges               

               11.3. Strategies for Market Access and Equity                     

               11.4. Patient Spending/Expenditure Analysis                      

                                            

12. Future Trends, Disruptions, and Opportunities                                           

               12.1. Analysis of Emerging Trends                           

               12.2. Technological Impact                         

               12.3. Impact of Potential Market Disruptors                        

               12.4. Opportunities for Future Development and Expansion                         

               12.5. Considerations for Investment Opportunities                           

                                            

13. Global Market Dynamics                                     

               13.1. Regional Regulatory Disparities                      

               13.2. Cross-Border Partnership Strategies                            

               13.3. Global Supply Chain Dynamics                       

               13.4. Case Studies: Success and Failure in Global Markets                             

               13.5. Strategies for Global Expansion and Localization                     

                                            

14. Company Profiles                                   

               14.1. Daiichi Sankyo                      

               14.2. Abbvie                     

               14.3. Eli Lilly and Company                         

               14.4. BioNTech SE                          

               14.5. Taiho Pharmaceutical                         

               14.6. Bristol Myers Squibb                          

               14.7. Bayer                       

               14.8. InventisBio                             

               14.9. Ono Pharmaceutical/Pierre Fabre                 

               14.10. Jiangsu Hengrui Medicine Co.                      

Download Sample

↻

The field with (*) is required.

Choose License Type

$

2500

$

4250

$

5250

$

6900

Request Sample
Customization
Ask an Expert
Enquire Before Buying
customer-support

Analyst Support

Every order comes with Analyst Support.

report-custom

Customization

We offer customization to cater your needs to fullest.

verify

Verified Analysis

We value integrity, quality and authenticity the most.

© 2025 Virtue Market Research. All Rights Reserved.